Introduction:
Plasmablastic lymphoma (PBL) is a rare and aggressive CD20-negative B-cell Non-Hodgkin Lymphoma (B-NHL) associated with modest outcomes in HIV positive, and poor outcomes in the HIV Negative. HIV-negative PBL patients are known to present with an advanced clinical stage (less common bone marrow involvement), B symptoms, and have significantly poorer outcomes when compared to HIV- positive patients (1). Multiple studies have shown median survival times of 12– 18 months.(1, 2)